Bentley Invests in the Future with New State-of-the-Art Facilities - European Medical Journal

Bentley Invests in the Future with New State-of-the-Art Facilities

Hechingen, Germany, 07 March, 2018

Key messages:

  • Bentley announces inauguration of the company’s new headquarters.
  • The new facilities will contain a large production site to help meet the growing demand for Bentley’s innovative product lines.
  • The move will have an immediate effect on the company’s capability and operations.

Bentley, a medical technology company that develops and manufactures innovative devices for the minimally invasive treatment of vascular diseases, announced today that it will officially open its new headquarters on 21 April 2018. The move to the state-of-the-art facilities, also in Hechingen, South Germany, where the company has been based since its foundation, marks a major milestone in Bentley’s young history and reflects its rapid growth and success.

The new headquarters will house all of Bentley’s operations, from research and development (R&D), quality control and manufacturing to administration, customer service and training. “Bentley has been expanding its market share at a very fast pace and our operations have, therefore, outgrown our old facilities,” says Sebastian Buechert, Sales & Marketing Director. “The move to a bigger and more modern space not only enables an increase in production capacity but also offers a better work environment to all Bentley’s employees.”

In the new building, workflows will be streamlined as all steps of production will be concentrated in one site. “The manufacturing area, which is four times bigger than in the old production site, is fully accredited and the first lot of devices built entirely on the new site was dispatched at the end of 2017. Bentley is proud of its credibility delivering products fast and reliably, and increasing capacity means we can improve customer satisfaction even further,” states Hartmut Grathwohl, Bentley’s Production Manager Grathwohl.

Miko Obradovic, Technical Director & Site Manager and one of Bentley’s two founders, comments that the new building will have both immediate and long-term effects on the company’s operations and performance. “Opening our new facilities will allow us to grow even more in the next few years, not only in terms of volume of production for the current portfolio, but also in the development of new products.”

Bentley is committed to research and development and is dedicated to pursuing new regulatory approvals – currently, the R&D team accounts for 20% of the workforce and the quality and regulatory department for 15%. “This is how we have been able to have our products approved in so many countries already, despite our devices being on the market for just over five years now. Following the substantial growth the company is seeing year on year, the new facilities certainly prepare Bentley for future growth,” adds Obradovic.

The new Bentley’s headquarters are located 300 metres away from the company’s previous site. The facilities have been designed incorporating high-end environmentally-friendly features throughout the building. The mayor of Hechingen will participate in the official opening.

About Bentley

Bentley was founded in 2009 by medical entrepreneurs Lars Sunnanväder and Miko Obradovic. The company has seen substantial growth since the launch of its first product in 2012 and today operates a global distribution network in more than 70 countries. The five top-line products in Bentley’s portfolio are:

  • BeGraft coronary, launched in 2012.
  • BeGraft peripheral: first generation, launched in 2013; second generation, launched in 2015.
  • BeSmooth peripheral, launched in 2014.
  • BeGraft aortic, launched in 2016.
  • BeGraft PLUS, launched in 2017.

 

Contacts

Rate this content's potential impact on patient outcomes

Average rating / 5. Vote count:

No votes so far! Be the first to rate this content.